fda shortage list tirzepatide Lilly's weight-loss drug removed from FDA's GLP-1 Drugs: FDA Removes Semaglutide

Animal studies have demonstrated anti-inflammatory effects of GLP-1 receptor agonists in models where weight loss was minimal or absent, suggesting direct pharmacological actions on inflammatory pathways

Laxative Types and Safety Considerations for GLP-1 Users Different laxative classes work through distinct mechanisms and carry different safety profiles when used with GLP-1 medications

Dietary and lifestyle interventions should be the first-line approach: Increase fibre intake : Aim for 2530 grams of fibre daily through wholegrains, fruits, vegetables, pulses, and seeds

GLP-1/GIP agonists: Increase fullness Reduce hunger and cravings Quiet food noise Slow gastric emptying (eat less, feel full longer) Improve insulin sensitivity and blood sugar This makes it dramatically easier to maintain the calorie deficit required for meaningful weight loss without constant hunger and food noise